In summary, our study demonstrated that Bru, a novel Akt1 inhibitor, effectively targeted Akt1 protein and suppressed its phosphorylation at Ser473 residues, which not only promoted mitochondria-mediated apoptosis via inhibiting the Akt1-phospho-Bad pathway in vitro and in vivo, but also impeded the ESCC cell’s metastasis via suppressing the Akt1 pathway in vitro. This evidence concerns the gene AKT1 and esophageal squamous cell carcinoma.